Get the Stockscreener App
1.21
7.63%
-0.10
After Hours:
1.16
-0.05
-4.13%
Werewolf Therapeutics Inc stock is traded at $1.21, with a volume of 1.56M.
It is down -7.63% in the last 24 hours and down -40.98% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$1.31
Open:
$1.26
24h Volume:
1.56M
Relative Volume:
2.10
Market Cap:
$55.33M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-1.1635
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-25.31%
1M Performance:
-40.98%
6M Performance:
+33.75%
1Y Performance:
-46.46%
1-Day Range:
$1.1601
$1.30
1-Week Range:
$1.08
$1.62
52-Week Range:
$0.595
$2.52
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
1.21 | 59.90M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -906.14M | -6.1812 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Luke Evnin Sells 55,795 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 60,369 Shares - MarketBeat
Bioventures 2014 L.P. Mpm Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 114,044 Shares of Stock - MarketBeat
Ansbert Gadicke Sells 86,936 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Ansbert Gadicke Sells 114,044 Shares - MarketBeat
Insider Selling: Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells 94,063 Shares of Stock - MarketBeat
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $121,341.27 in Stock - MarketBeat
Werewolf Therapeutics Narrows Losses And Wins FDA Fast Track Nod - Finimize
Werewolf Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - Investing News Network
Werewolf Therapeutics Q3 net loss narrows on lower R&D expenses - MarketScreener
Werewolf Therapeutics Inc. stock trend forecastQuarterly Profit Review & Free Expert Approved Momentum Trade Ideas - newser.com
Advanced analytics toolkit walkthrough for Werewolf Therapeutics Inc.Market Risk Summary & Fast Gain Swing Alerts - newser.com
Is Werewolf Therapeutics Inc. reversing from oversold territory2025 Top Decliners & Proven Capital Preservation Methods - newser.com
How Werewolf Therapeutics Inc. stock performs after earningsPortfolio Performance Summary & Step-by-Step Swing Trade Plans - newser.com
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsStop Loss & Capital Efficient Trade Techniques - newser.com
Visual trend scoring systems applied to Werewolf Therapeutics Inc.July 2025 Decliners & Accurate Technical Buy Alerts - newser.com
How to read the order book for Werewolf Therapeutics Inc.July 2025 Macro Moves & Community Supported Trade Ideas - newser.com
Werewolf therapeutics director Evnin sells $251k in HOWL stock By Investing.com - Investing.com Canada
Werewolf therapeutics director Evnin sells $251k in HOWL stock - Investing.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Werewolf Therapeutics Inc (HOWL) - setenews.com
Is Werewolf Therapeutics Inc. stock bottoming outJuly 2025 EndofMonth & Comprehensive Market Scan Insights - newser.com
What MACD signals say about Werewolf Therapeutics Inc.Global Markets & AI Driven Price Predictions - newser.com
Will Werewolf Therapeutics Inc. stock recover faster than marketQuarterly Trade Review & Verified Entry Point Detection - newser.com
Will Werewolf Therapeutics Inc. price bounce be sustainable2025 Top Decliners & Entry Point Confirmation Alerts - newser.com
Will Werewolf Therapeutics Inc. stock outperform growth indexesWeekly Trade Analysis & Weekly High Conviction Ideas - newser.com
Werewolf Therapeutics Inc. stock trendline breakdownJuly 2025 Retail & Technical Pattern Alert System - newser.com
Identifying reversal signals in Werewolf Therapeutics Inc.Price Action & AI Driven Stock Movement Reports - newser.com
Predicting Werewolf Therapeutics Inc. trend using moving averagesEntry Point & Risk Managed Investment Signals - newser.com
Werewolf Therapeutics Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Will Werewolf Therapeutics Inc. stock reach all time highs in 2025Weekly Profit Analysis & Weekly High Return Forecasts - newser.com
Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Sells $113,271.52 in Stock - MarketBeat
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):